Protalix BioTherapeutics, Inc. (PLX)
USD 2.26
(-3.63%)
USD 2.26
(-3.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 11.65 Million USD | 208.06% |
| 2022 | -10.78 Million USD | 46.25% |
| 2021 | -18.94 Million USD | -737.26% |
| 2020 | 4.45 Million USD | 136.21% |
| 2019 | -8.69 Million USD | 53.69% |
| 2018 | -17.1 Million USD | 48.09% |
| 2017 | -71.79 Million USD | -18.22% |
| 2016 | -16.52 Million USD | -29.91% |
| 2015 | -21.17 Million USD | 5.84% |
| 2014 | -25.41 Million USD | -6.07% |
| 2013 | -23.57 Million USD | -178.03% |
| 2012 | -7.92 Million USD | 74.22% |
| 2011 | -32.9 Million USD | 8.7% |
| 2010 | -26.83 Million USD | -20.21% |
| 2009 | -29.97 Million USD | -31.08% |
| 2008 | -21.18 Million USD | 3.96% |
| 2007 | -21.78 Million USD | -156.92% |
| 2006 | -8.99 Million USD | -9405.79% |
| 2005 | -5.47 Million USD | 41.11% |
| 2004 | -2.29 Million USD | -12.35% |
| 2003 | -147.38 Thousand USD | 11.27% |
| 2002 | -166.1 Thousand USD | 43.07% |
| 2001 | -291.78 Thousand USD | 45.16% |
| 2000 | -532.08 Thousand USD | -33.51% |
| 1999 | -653.01 Thousand USD | 58.99% |
| 1998 | -971.86 Thousand USD | -491.22% |
| 1997 | -164.38 Thousand USD | -273.1% |
| 1996 | -44.05 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.53 Million USD | 24.69% |
| 2024 Q2 | -2.1 Million USD | 60.56% |
| 2023 Q1 | -2.28 Million USD | -0.09% |
| 2023 FY | - USD | 208.06% |
| 2023 Q3 | -1.88 Million USD | -109.01% |
| 2023 Q2 | 20.95 Million USD | 1016.13% |
| 2023 Q4 | -5.3 Million USD | -180.98% |
| 2022 Q1 | -1.39 Million USD | 75.72% |
| 2022 Q2 | -4.44 Million USD | -217.81% |
| 2022 Q3 | -2.65 Million USD | 40.24% |
| 2022 FY | - USD | 46.25% |
| 2022 Q4 | -2.28 Million USD | 13.94% |
| 2021 Q2 | -8.75 Million USD | -188.49% |
| 2021 Q1 | -3.03 Million USD | -203.94% |
| 2021 Q3 | -1.5 Million USD | 82.81% |
| 2021 FY | - USD | -737.26% |
| 2021 Q4 | -5.75 Million USD | -282.91% |
| 2020 Q4 | 2.91 Million USD | 234.91% |
| 2020 Q1 | 5.27 Million USD | 88.83% |
| 2020 Q2 | -1.86 Million USD | -135.43% |
| 2020 Q3 | -2.16 Million USD | -15.79% |
| 2020 FY | - USD | 136.21% |
| 2019 Q3 | -1.08 Million USD | 80.04% |
| 2019 FY | - USD | 53.69% |
| 2019 Q1 | -4.93 Million USD | -140.97% |
| 2019 Q2 | -5.45 Million USD | -10.49% |
| 2019 Q4 | 2.79 Million USD | 356.38% |
| 2018 Q4 | 12.05 Million USD | 190.5% |
| 2018 Q3 | -13.32 Million USD | -46.64% |
| 2018 Q1 | -6.75 Million USD | 45.78% |
| 2018 FY | - USD | 48.09% |
| 2018 Q2 | -9.08 Million USD | -34.59% |
| 2017 FY | - USD | -18.22% |
| 2017 Q2 | -10.27 Million USD | -141.78% |
| 2017 Q4 | -12.44 Million USD | -71.14% |
| 2017 Q3 | -7.27 Million USD | 29.18% |
| 2017 Q1 | -4.24 Million USD | -172.99% |
| 2016 Q1 | -7.1 Million USD | 34.99% |
| 2016 Q3 | -5.89 Million USD | 36.9% |
| 2016 Q2 | -9.34 Million USD | -31.51% |
| 2016 FY | - USD | -29.91% |
| 2016 Q4 | 5.82 Million USD | 198.69% |
| 2015 Q2 | -3.82 Million USD | 8.98% |
| 2015 FY | - USD | 5.84% |
| 2015 Q4 | -10.93 Million USD | -396.37% |
| 2015 Q3 | -2.2 Million USD | 42.39% |
| 2015 Q1 | -4.19 Million USD | 33.37% |
| 2014 FY | - USD | -6.07% |
| 2014 Q4 | -6.3 Million USD | -17.38% |
| 2014 Q1 | -5.6 Million USD | 39.75% |
| 2014 Q3 | -5.36 Million USD | -20.79% |
| 2014 Q2 | -4.44 Million USD | 20.65% |
| 2013 Q1 | -3.5 Million USD | 62.12% |
| 2013 Q3 | -4.77 Million USD | 20.46% |
| 2013 FY | - USD | -178.03% |
| 2013 Q4 | -9.29 Million USD | -94.76% |
| 2013 Q2 | -6 Million USD | -71.34% |
| 2012 FY | - USD | 74.22% |
| 2012 Q4 | -9.24 Million USD | -98.95% |
| 2012 Q3 | -4.64 Million USD | -140.75% |
| 2012 Q1 | -5.13 Million USD | 35.21% |
| 2012 Q2 | 11.4 Million USD | 322.1% |
| 2011 Q3 | -7.87 Million USD | -4.06% |
| 2011 Q2 | -7.56 Million USD | -81.8% |
| 2011 Q1 | -4.16 Million USD | 75.76% |
| 2011 Q4 | -7.92 Million USD | -0.7% |
| 2011 FY | - USD | 8.7% |
| 2010 Q2 | -9.39 Million USD | -26.53% |
| 2010 Q3 | -2.05 Million USD | 78.08% |
| 2010 FY | - USD | -20.21% |
| 2010 Q4 | -17.16 Million USD | -733.56% |
| 2010 Q1 | -7.42 Million USD | 48.57% |
| 2009 Q4 | -14.43 Million USD | -159.2% |
| 2009 Q3 | -5.56 Million USD | -3.13% |
| 2009 Q2 | -5.39 Million USD | -17.88% |
| 2009 FY | - USD | -31.08% |
| 2009 Q1 | -4.58 Million USD | 22.61% |
| 2008 Q2 | -4.57 Million USD | 23.71% |
| 2008 FY | - USD | 3.96% |
| 2008 Q4 | -5.91 Million USD | 7.14% |
| 2008 Q1 | -6 Million USD | -3.63% |
| 2008 Q3 | -6.37 Million USD | -39.21% |
| 2007 Q2 | -12.97 Million USD | -255.63% |
| 2007 FY | - USD | -156.92% |
| 2007 Q4 | -5.79 Million USD | 6.26% |
| 2007 Q3 | -6.17 Million USD | 52.39% |
| 2007 Q1 | -3.64 Million USD | 62.01% |
| 2006 Q2 | -74.11 Thousand USD | -251.06% |
| 2006 Q1 | -21.11 Thousand USD | 19.12% |
| 2006 FY | - USD | -9405.79% |
| 2006 Q4 | -9.6 Million USD | -8067.11% |
| 2006 Q3 | -117.62 Thousand USD | -58.71% |
| 2005 FY | - USD | 41.11% |
| 2005 Q4 | -26.1 Thousand USD | 27.26% |
| 2005 Q3 | -35.88 Thousand USD | -45.52% |
| 2005 Q2 | -24.65 Thousand USD | -127.0% |
| 2005 Q1 | -10.86 Thousand USD | 66.17% |
| 2004 Q3 | -43.88 Thousand USD | 26.75% |
| 2004 Q1 | -29.68 Thousand USD | 39.24% |
| 2004 Q2 | -59.9 Thousand USD | -101.82% |
| 2004 Q4 | -32.1 Thousand USD | 26.83% |
| 2004 FY | - USD | -12.35% |
| 2003 Q1 | -34.55 Thousand USD | 34.23% |
| 2003 FY | - USD | 11.27% |
| 2003 Q2 | -30.96 Thousand USD | 10.39% |
| 2003 Q3 | -33.01 Thousand USD | -6.64% |
| 2003 Q4 | -48.85 Thousand USD | -47.96% |
| 2002 Q1 | -40.77 Thousand USD | 73.9% |
| 2002 Q2 | -37.03 Thousand USD | 9.16% |
| 2002 Q4 | -52.53 Thousand USD | -46.9% |
| 2002 Q3 | -35.76 Thousand USD | 3.45% |
| 2002 FY | - USD | 43.07% |
| 2001 Q3 | -58.67 Thousand USD | 9.8% |
| 2001 FY | - USD | 45.16% |
| 2001 Q2 | -65.04 Thousand USD | -450.17% |
| 2001 Q1 | -11.82 Thousand USD | 96.51% |
| 2001 Q4 | -156.24 Thousand USD | -166.3% |
| 2000 Q3 | -15.57 Thousand USD | 85.84% |
| 2000 FY | - USD | -33.51% |
| 2000 Q1 | -68.17 Thousand USD | -138.57% |
| 2000 Q4 | -338.37 Thousand USD | -2072.95% |
| 2000 Q2 | -109.95 Thousand USD | -61.28% |
| 1999 Q2 | -151.6 Thousand USD | -189.63% |
| 1999 Q1 | -12.1 Thousand USD | 139.61% |
| 1999 FY | - USD | 58.99% |
| 1999 Q4 | -77.89 Thousand USD | 129.09% |
| 1999 Q3 | -411.4 Thousand USD | -116.71% |
| 1998 Q1 | -210 Thousand USD | -10.53% |
| 1998 Q2 | -10 Thousand USD | 95.24% |
| 1998 Q3 | 90 Thousand USD | 1000.0% |
| 1998 Q4 | -790 Thousand USD | -977.78% |
| 1998 FY | - USD | -491.22% |
| 1997 Q2 | -140 Thousand USD | -40.0% |
| 1997 Q3 | -200 Thousand USD | -42.86% |
| 1997 Q4 | -190 Thousand USD | 5.0% |
| 1997 FY | - USD | -273.1% |
| 1997 Q1 | -100 Thousand USD | -141.67% |
| 1996 FY | - USD | 0.0% |
| 1996 Q3 | 110 Thousand USD | 0.0% |
| 1996 Q4 | 240 Thousand USD | 118.18% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 136.779% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 129.187% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 122.787% |
| Azitra, Inc. | -10.67 Million USD | 209.161% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | 242.433% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | 269.783% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 140.738% |
| CEL-SCI Corporation | -27.56 Million USD | 142.274% |
| iBio, Inc. | -14.02 Million USD | 183.097% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 147.107% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 157.729% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | 151.045% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 183.971% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | 342.729% |
| NanoViricides, Inc. | -7.75 Million USD | 250.198% |
| Oragenics, Inc. | -20.87 Million USD | 155.806% |
| BiomX Inc. | -22.81 Million USD | 151.067% |
| BiomX Inc. | -22.81 Million USD | 151.067% |
| Palatin Technologies, Inc. | -29.03 Million USD | 140.133% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 133.21% |
| Theriva Biologics, Inc. | -19.85 Million USD | 158.683% |